Editas Medicine Inc (NASDAQ:EDIT) shares, rose in value on Thursday, July 10, with the stock price down by -0.65% to the previous day’s close as strong demand from buyers drove the stock to $3.06.
Actively observing the price movement in the last trading, the stock closed the session at $3.08, falling within a range of $2.99 and $3.18. The value of beta (5-year monthly) was 2.096. Referring to stock’s 52-week performance, its high was $6.05, and the low was $0.91. On the whole, EDIT has fluctuated by 58.55% over the past month.
With the market capitalization of Editas Medicine Inc currently standing at about $256.17 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that EDIT’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of EDIT currently trading nearly 29.91% and 59.45% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 74.87, while the 7-day volatility ratio is showing 10.82% which for the 30-day chart, stands at 12.13%. Furthermore, Editas Medicine Inc (EDIT)’s beta value is 2.18.
A comparison of Editas Medicine Inc (EDIT) with its peers suggests the former has fared considerably weaker in the market. EDIT showed an intraday change of -0.65% in last session, and over the past year, it grew by 140.94%%.
Data on historical trading for Editas Medicine Inc (NASDAQ:EDIT) indicates that the trading volumes over the past 10 days have averaged 3.93 and over the past 3 months, they’ve averaged 2.37 million. According to company’s latest data on outstanding shares, there are 83.71 million shares outstanding.
Nearly 0.91% of Editas Medicine Inc’s shares belong to company insiders and institutional investors own 54.26% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.43 million shares as on 2025-06-13, resulting in a short ratio of 4.26. According to the data, the short interest in Editas Medicine Inc (EDIT) stood at 1009.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 9.09 million. The stock has fallen by -36.51% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EDIT stock heading into the next quarter.
